The present invention relates to an active (immunostimulatory) compositioncomprising at least one RNA, preferably an mRNA, encoding at least two (preferablydifferent) antigens capable of eliciting an (adaptive) immune response in amammal wherein the antigens are selected from the group consisting of PSA (Prostate-SpecificAntigen), PSMA (Prostate- Specific Membrane Antigen), PSCA (Prostate StemCell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate).The invention furthermore relates to a vaccine comprising said active (immunostimulatory)composition, and to the use of said active (immunostimulatory) composition(for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive)immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvantand/or hormone-refractory prostate cancers, and diseases or disorders relatedthereto.. Finally, the invention relates to kits, particularly to kits of parts,containing the active (immunostimulatory) composition and/or the vaccine.
